All-in-one biointelligence ecosystem unifying AI, data, and advanced lab research to create biologics breakthroughs.
Joined November 2019
- Tweets 1,342
- Following 2,306
- Followers 903
- Likes 2,291
192 Photos and videos
RT @ImmunoPrecise: 𝗢𝗻𝗲 𝗯𝗿𝗮𝗻𝗱. 𝗘𝘅𝗽𝗼𝗻𝗲𝗻𝘁𝗶𝗮𝗹 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆.
Earlier today, we announced our transition to MindWalk™ (NASDA…
8
RT @ImmunoPrecise: Press release: ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”.
Today, IPA (ImmunoPrecise…
7
21 Jan 2025
In this insightful blog by our data scientist, Sébastien Lemal, we explore AlphaFold 3’s potential and how BioStrand’s LENSᵃⁱ platform leverages these breakthroughs to accelerate biotherapeutic development.
Read our blog: blog.biostrand.ai/beyond-alp…
2
269
31 Dec 2024
RT @ImmunoPrecise: 2024: A Year of Transformative Progress in Biotherapeutics
This year, we harnessed the power of the LENSᵃⁱ platform pow…
2
RT @ImmunoPrecise: Catch Dr. Jennifer Bath's insightful Nasdaq interview with Jane King and Ari Zoldan, airing Saturday, September 28th! Dr…
4
Data integration in #antibodydiscovery doesn’t have to be complex. With LENSᵃⁱ, streamline multi-omics data at the subsequence level for faster, sharper insights.
From target discovery to lead optimization, we help you make informed decisions quickly. 26206544.fs1.hubspotusercont…
2
5
306
RT @ImmunoPrecise: Press Release: ImmunoPrecise Antibodies successfully engineers in silico antibodies to elusive tumor protein using its p…
3
11 Jul 2024
In her latest blog, Julie Delanote, Data Scientist at BioStrand, explores how vector search and integrated AI technologies are transforming drug discovery by analyzing proteins at the sub-sequence level.
Read the blog: blog.biostrand.ai/vector-sea…
2
4
271
RT @ImmunoPrecise: Tech update! Tune in to Jennifer Bath and Radius Research discussing the innovative LENSᵃⁱ™ Integrated Intelligence Plat…
5
Our latest article explores how #insilico methods enhance #drugdevelopment by providing rapid insights, early identification of potential failures, and cost-effective streamlining.
Read our blog: blog.biostrand.ai/immunogeni…
#BioStrandBlogs #Immunogenicity #DrugDiscovery $IPA
1
6
470
RT @ImmunoPrecise: ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer.
Ms. Taylor is a seasoned financial executive with e…
3
RT @ImmunoPrecise: IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Partnership to Develop First-In-Class AI Model for Pharmacogenom…
6
14 Jun 2024
In our latest blog post, Saskia Debergh, BioStrand computational linguist, explains why vector search is essential for finding precise information in vast data sets through advanced text analysis.
Read more in our blog: blog.biostrand.ai/vector-sea…
$IPA #BioStrandBlogs
3
9
594
14 Jun 2024
RT @ImmunoPrecise: BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with…
8
14 Jun 2024
RT @ImmunoPrecise: IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR).
BioStra…
7
13 Jun 2024
RT @ImmunoPrecise: ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSᵃⁱ™ Tec…
3
30 May 2024
Our latest blog presents a detailed case study on the LENSᵃⁱ™ approach to in silico epitope binning, validated against traditional wet lab techniques. Discover how this innovation enhances scalability and accuracy in therapeutic mAb development.
blog.biostrand.ai/in-silico-…
$IPA
3
8
554
29 May 2024
RT @ImmunoPrecise: Discover how the collaboration between IPA subsidiary BioStrand and InterSystems is transforming technology and #drugdis…
6
23 May 2024
Explore our latest article to see how this technique improves data retrieval across diverse #unstructureddata types. Learn about its applications in #drugdiscovery and #healthcare, and why it's crucial for modern data-driven solutions.
Read now: biostrand.ai/vector-search
$IPA
2
6
610
15 May 2024
Edward steps into the role of Director of Sales Europe, bringing over two decades of experience in pharma and biotech. He will be focusing on guiding both BioStrand and IPA through exciting new research collaborations across Europe.
Read his interview: blog.biostrand.ai/employee-s…
2
10
265